Group 1 - The 44th J.P. Morgan Healthcare Conference is set to take place in San Francisco on January 12, 2026, featuring multiple Chinese innovative pharmaceutical companies [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, and 3SBio, will participate in the Asia-Pacific session, highlighting the growing presence of Chinese firms in the global market [1] Group 2 - Guotai Junan Securities views the conference as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, driven by advancements in global clinical trials, significant data releases, and an optimized competitive landscape [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1] Group 3 - The Hong Kong Stock Connect Medical ETF (520510) has over 27% weight in WuXi-related companies and more than 25% exposure to AI healthcare [2] - The Hang Seng Medical ETF (159892) focuses on the innovative drug sector and is the largest in scale within its index [3]

Group 1 - The core viewpoint of the articles highlights a significant rise in Chinese innovative pharmaceutical stocks, driven by the upcoming 44th JPMorgan Healthcare Conference, where multiple Chinese companies are set to showcase their products [1][2] - Notable stock performances include a 6.35% increase for 3SBio, a 7.22% increase for WuXi AppTec, and a 6.64% increase for Lepu Biopharma, indicating strong market interest in these companies [1] - The conference serves as a critical platform for domestic pharmaceutical companies to demonstrate their core molecular product capabilities and advance overseas business development collaborations [2] Group 2 - The industry is transitioning back to a phase of global value verification for products, with a focus on global clinical advancements and the release of significant data [2] - Chinese innovative drug valuations have shifted from being perceived as "assets to be bought" to a stage of "global value," reflecting a broader recognition of their potential in the international market [2] - The Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly contributing to new growth trajectories for companies [2]

Core Viewpoint - The innovative pharmaceutical stocks have shown significant gains, driven by the upcoming 44th JPMorgan Healthcare Conference, where multiple Chinese innovative drug companies are set to participate [1] Group 1: Stock Performance - Innovent Biologics (01530) increased by 6.35%, trading at HKD 28.82 [1] - WuXi AppTec (02359) rose by 7.22%, trading at HKD 118.8 [1] - Lepu Biopharma-B (02157) saw a rise of 6.64%, trading at HKD 28.9 [1] - Galenica-B (01672) increased by 4.09%, trading at HKD 12.97 [1] - Genscript Biotech (01952) rose by 3.97%, trading at HKD 40.84 [1] Group 2: Conference Participation - The 44th JPMorgan Healthcare Conference is set to begin on January 12, 2026, in San Francisco, with several Chinese innovative drug companies confirming their attendance [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, Innovent Biologics, and Rongchang Biologics, will participate in the Asia-Pacific session [1] Group 3: Industry Insights - According to Guojin Securities, the conference serves as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, with ongoing clinical advancements, significant data releases, and improved competitive dynamics driving multiple rounds of revaluation for product global value and corporate valuations [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1]

Core Viewpoint - The antibacterial drug market in China is under pressure, with sales expected to drop below 100 billion yuan in 2024 and continue declining by approximately 18% in the first three quarters of 2025, reaching over 60 billion yuan [1][14]. Market Performance - The total sales of systemic antibacterial drugs in public medical institutions in China have been declining, with a significant drop in sales from 2024 to 2025 [1][14]. - The market for systemic antibacterial drugs includes 12 major therapeutic categories, with cephalosporins leading but experiencing four consecutive years of sales decline from 2022 to the first three quarters of 2025 [3][16]. Company Rankings - In the ranking of major companies, Pfizer, China National Pharmaceutical Group, and North China Pharmaceutical Group hold the top three positions, with sales exceeding 6.2 billion yuan, 2.1 billion yuan, and 1.9 billion yuan respectively in the first three quarters of 2025 [5][18]. - Nanjing Youke Biological, ranked fifteenth, showed remarkable growth with a year-on-year increase of 137.17%, marking its first entry into the top 20 groups [5][18]. Product Performance - The top 20 systemic antibacterial drugs accounted for over 50% of the market share, with the leading product, injectable cefoperazone/sulbactam (2:1), achieving sales of over 4.5 billion yuan [21][22]. - Notably, the compound injection of cefoperazone/sulbactam saw a dramatic increase of 219.32%, marking a significant rise in its market presence [21][23]. National Procurement Impact - Among the top 20 products, 15 have been included in the national procurement program, with 13 experiencing double-digit declines in sales [21][23]. - The tenth batch of national procurement saw injectable piperacillin/tazobactam drop by 55.61%, while the eleventh batch saw injectable cefoperazone/sulbactam decline by 47.56% [21][23]. New Drug Development - Currently, there are no domestic class 1 new drugs among the top 20 systemic antibacterial products, although five class 1 new antibacterial drugs have been approved since 2021 [25][26]. - Eight products meet the criteria for national procurement inclusion, with seven being injectable forms and one oral formulation [25][26].

Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02% to a price of 0.555, with a trading volume of 95,100 shares [2]. - Major constituents of the ETF include: - InnoCare Pharma-B (映恩生物-B) up over 6% - Hutchison China MediTech (和黄医药) up over 4% [1][2]. Group 2: Regulatory and Company Developments - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed overseas marketed original and generic drugs in China [1][3]. - Recent announcements from innovative drug companies include: - Sinopharm's SAL0145 injection clinical trial application accepted by NMPA [3]. - Hengrui Medicine's approval for its innovative drug Rilapladib injection [3]. Group 3: Investment Sentiment and Recommendations - Recent reports from securities firms such as Pacific Securities, Guotai Junan, and Industrial Securities are bullish on the innovative drug sector, emphasizing the importance of "innovation + internationalization" as a core theme for the pharmaceutical sector by 2026 [3][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three key advantages: 1. Pure and comprehensive coverage of innovative drug R&D companies [4]. 2. High concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5]. 3. Controlled risks through forced de-weighting of less liquid constituent stocks [4].

Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02%, reaching a price of 0.555 [2]. - Major components of the ETF, such as InnoCare Pharma-B and Hutchison China MediTech, saw significant gains of over 6% and 4%, respectively [1][3]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin original and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and effectively controls risks associated with less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 73% of its weight, highlighting the dominance of leading innovative drug companies [5].

Group 1 - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, up 2% and surpassing the 60-day moving average [1][8] - Major components of the ETF include companies like InnoCare Pharma-B, which rose over 6%, and Hutchison China MediTech, which increased by over 4% [1][8] - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin drugs and generics in China [1][10] Group 2 - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Ruilafup α injection by Hengrui Medicine [3][10] - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3][10] - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [3][10] Group 3 - The top ten holdings in the Hong Kong Stock Connect Innovative Drug ETF account for over 73% of the total weight, indicating a strong presence of leading companies in the innovative drug sector [4][11] - Notable companies in the ETF include Kangfang Biologics (10.49% weight), BeiGene (10.01%), and CSPC Pharmaceutical Group (9.97%), among others, with a total market capitalization of approximately HKD 11.35 billion [4][11] - For investors looking to reduce volatility while still focusing on innovative drugs, the market offers the only pharmaceutical ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a more stable investment option [4][12]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Market Overview - On January 7, U.S. stock indices experienced a late-session drop, with the Dow Jones Industrial Average and S&P 500 declining by 0.94% and 0.34% respectively, while the Nasdaq index rose by 0.16% [2] - Major technology stocks showed mixed performance, with the U.S. tech giants index increasing by 0.56%. Alphabet-C rose by 2.52%, Microsoft by 1.07%, Nvidia by 1.03%, and Amazon by 0.29%. In contrast, Tesla fell by 0.36%, Apple by 0.77%, and META by 1.81% [4] Financial Sector - The financial sector saw a collective decline, with JPMorgan down by 2.26%, Goldman Sachs by 1.62%, Citigroup by 0.93%, Morgan Stanley by 1.59%, Bank of America by 2.83%, and Wells Fargo by 2.19% [5] Chinese Stocks - Chinese stocks listed in the U.S. had mixed results, with the Nasdaq Golden Dragon China Index dropping by 1.58%. Notable gainers included Su Xuan Tang Pharmaceutical up over 18%, Dingdong Maicai up over 8%, and iQIYI and Youdao each up over 5%. Conversely, Alibaba, Kingsoft Cloud, and TAL Education fell by over 2%, while NetEase, Beike, and Qifu Technology dropped by over 3% [5] Commodity Market - In the commodity market, precious metals experienced significant volatility. As of January 7, London spot gold fell by 0.87% to $4,456.07 per ounce, while COMEX gold futures dropped by 0.65% to $4,467.10 per ounce. London spot silver decreased by 3.56%, with intraday losses exceeding 6%, and COMEX silver futures fell by 3.77% [6] - Basic metals also saw declines, with LME copper down nearly 3% and LME nickel down over 4% [6] Oil Market - International crude oil prices declined, with both ICE Brent and NYMEX WTI crude experiencing drops [7] Employment and Economic Data - In employment data, the U.S. ADP employment number for December 2025 increased by 41,000, below the expected increase of 47,000. The previous value was revised from a decrease of 32,000 to a decrease of 29,000. The ISM Non-Manufacturing PMI for December 2025 was reported at 54.4, exceeding the expected 52.3 and the previous value of 52.6. Factory orders in October 2025 decreased by 1.3%, compared to an expected decrease of 1.2% and a previous increase of 0.2% [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 再鼎醫藥有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09688 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.000006 | USD | | 30,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.000006 | USD | | 30,000 | 本月底法定/註 ...